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Abstract
　　Down syndrome (DS) is associated with impairment of cognitive ability and physical growth, and congenital heart disease. 
Additionally, in patients with DS, it has an increased risk for diseases such as Alzheimerʼs disease and leukemia. DS is a 
congenital disorder caused by having an extra 21st chromosome. The overall rate of incidence of Downʼs syndrome is one in 
every 700 births. Currently, prenatal diagnosis for DS carried out, such as amniocentesis, chorionic villi sampling, 
ultrasonography and maternal serum screening tests. This screening test is desirable to a sensitive serum marker that can be 
measured a cheap, accurate, rapidly, and noninvasive test. Since a few years, proteomics allows the simultaneous analysis of 
hundreds of proteins, as well as the analysis of their structural modifications. It is aid in discovery of novel biomarkers for better 
screening. A total of 542 proteins have been identified from the triplicate analyses by the LTQ-Orbitrap mass spectrometer. 
Comparison between the two groups revealed 60 candidates that showed greater than 2-fold increase or decrease in the presence 
of DS. Among these candidates, amyloid precursor protein and tenascin-C were verified by ELISA. This review introduces the 
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定成績は、個体によるバラツキは大きいが、平均値でみ
ると239mL（15 ～ 16週）、669mL（25 ～ 26週）と妊娠週







































　 現 在 ま で に 使 用 さ れ た 物 質 と し て は、congo red
（Dickmann ８, 1933）、phenol red（Albano ９, 1933）、inulin
（Lambiotte10, 1949）、RISA、重水、Evans blue（Nelson11, 
1965）、coomassie blue（Elliot12, 13, 1961）、パラアミノ馬






















































































































































表１．羊水中の pH, PCO2, HCO3
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を 指 標 と し て い る 報 告 が 多 い が、 こ の 場 合 に は、
sphingomyelin 量が少ない場合にも、相対的に L/S 比が上
昇するため、lecithin 量を指標としたほうが良いとする報



































　α-globulin は、10 ～ 12% を占める。α２-globulin に属
する mucoprotein は、胎盤に多く含まれているが、重症
妊娠中毒症や低体重児の際には、羊水中に増えるとい
う36。α２-globulin に属する ceruloplasmin は羊水中の銅イ
オンと結合して存在する。
　β-globulin は、15~16% を占める。β１-globulin に属す











免疫 globulin では、IgM は無いとされている。IgA およ





IgG を高濃度に認めた。Monif ら41も IgG の存在を報告し













































































































uronate 55%、sulfate 35%、free 10%、であり、この比率
は、予定日近い胎児尿と同様である。一方、臍帯血では、
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羊水分析 羊水中ビリルビン様物質判定 Rh 不適合妊娠
表２．羊水穿刺による検査法と適応
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fetal swallowing により unconjugated bilirubin が、肝で抱
合化され、胎盤より排出されるものと考えられる。





















後 判 定、 羊 水 鏡 に よ る 羊 水 混 濁 の 有 無 に よ る fetal 



































































associated plasma protein A（PAPP-A）、ヒト絨毛性胎盤刺
激ホルモン（human chorionic gonadotoropin；hCG）のβ























































































































を同定するパスウェイ解析ソフト Ingenuity Pathways 
sample karyotype gestation
DS1 47, XY, +21 17.5
DS2 47, XX, +21 16
DS3 47, XX, +21 19.3
DS4 47, XY, +21 19.6
DS5 47, XX, +21 17
DS6 47, XY, +21 18.5
DS7 47, XX, +21 16.5
DS8 47, XY, +21 16.3
DS9 47, XX, +21 18.6
DS10 47, XY, +21 19.2
sample karyotype gestation
CN1 46, XY 17.5
CN2 46, XX 16
CN3 46, XX 18.2
CN4 46, XX 19.2
CN5 46, XX 18
CN6 46, XY 18.2
CN7 46, XY 16
CN8 46, XY 16.6
CN9 46, XX 18.5









































































































A disintegrin and metalloproteinase
with thrombospondin motifs 1
A disintegrin and metalloproteinase
with thrombospondin motifs 5
Isoform APP770 of Amyloid beta 
A4 protein
Collagen alpha-1(VI) chain
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図２．DS-AF で際立って減少を示したタンパク質リストの上位パスウェイ。 　　　
　　　   このパスウェイは、臓器形態、生殖器系発達と機能、脂質代謝に関係している。
gene protein name
ABI3BP Isoform 2 of Target of Nesh-SH3
ABP1 Isoform 1 of Amiloride-sensitive amine oxidase
ADAMTS1 A disintegrin and metalloproteinase with
thrombospondin motifs 1
ANTXR1 Isoform 1 of Anthrax toxin receptor 1
APP Isoform APP770 of Amyloid beta A4 protein
ATP6AP1 V-type proton ATPase subunit S1
C1RL Complement C1r subcomponent-like protein
C8B Complement component C8 beta chain
CA1 Carbonic anhydrase 1
CEL carboxyl ester lipase precursor
CGB Choriogonadotropin subunit beta
COL4A2 Collagen alpha-2(IV) chain
COL5A2 Collagen alpha-2(V) chain
COMP Cartilage oligomeric matrix protein
CPA1 Carboxypeptidase A1
CRK Isoform Crk-II of Proto-oncogene C-crk
CRNN Cornulin
CSPG4 Chondroitin sulfate proteoglycan 4
CST6 Cystatin-M
CTGF Isoform 1 of Connective tissue growth factor
DPP4 Dipeptidyl peptidase 4
FBN2 fibrillin 2 precursor
FLNA Isoform 2 of Filamin-A
FOLH1 Isoform PSMA-1 of Glutamate carboxypeptidase 2
GC vitamin D-binding protein precursor
GGT1 Isoform 1 of Gamma-glutamyltranspeptidase 1
HAPLN1 Hyaluronan and proteoglycan link protein 1
IGFBP5 Insulin-like growth factor-binding protein 5
LAMA5 Laminin subunit alpha-5
LDHB L-lactate dehydrogenase B chain
MME Neprilysin
MMP2 7 2 kDa type IV collagenase
MUC13 Mucin-13
MUC5AC Mucin-5AC (Fragment)
NID1 Isoform 1 of Nidogen-1
NPC2 cDNA FLJ59142, highly similar to Epididymal
secretory protein E1
NRP1 Muscle type neuropilin 1
NT5E 5′-nucleotidase
PDIA6 Isoform 2 of Protein disulfide-isomerase A6
PLOD1 cDNA FLJ59393, highly similar to
Procollagen-lysine,2-oxoglutarate5-dioxygenase 1
PLUNC Protein Plunc
PSG2 Pregnancy-specific beta-1-glycoprotein 2
PSG9 Pregnancy-specific beta-1-glycoprotein 9
SCGB3A2 Secretoglobin family 3A member 2
SERPINA5 Plasma serine protease inhibitor
SERPINC1 SERPINC1 protein
SERPINE1 Plasminogen activator inhibitor 1
SFN Isoform 1 of 14-3-3 protein sigma
SI Sucrase-isomaltase, intestinal
SPINK5 Serine protease inhibitor Kazal-type 5
SPRR1B Cornifin-B
SPRR3 Small proline-rich protein 3
TAGLN2 Transgelin-2
TF 11 kDa protein
TNC Isoform 1 of Tenascin
TUBA1B Tubulin alpha-1B chain
TXN Thioredoxin
VCAM1 Isoform 1 of Vascular cell adhesion protein 1
VCAN Isoform V1 of Versican core protein













































































（a）APP； （b）TNC-C, CN= 染色体性正常と DS= ダウン症妊娠
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